Could some esophageal cancer patients skip surgery? new trial tests a less invasive option
NCT ID NCT07162506
First seen Jun 25, 2026 · Last updated Jun 25, 2026
Summary
This study looks at two approaches for people with a type of esophageal cancer that shrank after initial chemo-immunotherapy. One group will have surgery to remove the tumor, while the other will get a combination of radiation and chemotherapy instead. Both groups will also receive maintenance immunotherapy for up to a year. The goal is to see if the non-surgical approach can control the cancer just as well while possibly avoiding the risks of major surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin Cancer Hospital
RECRUITINGTianjin, Tianjin Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Camrelizumab (immunotherapy), nab-paclitaxel (chemotherapy), carboplatin (chemotherapy), radiotherapy (radiation)
What this could lead to
If successful, this could show that some esophageal cancer patients can avoid major surgery and still control their disease with a combination of radiation, chemo, and immunotherapy.
What could go wrong
This is a Phase II trial with only 120 participants, so results are preliminary. The non-surgery group may have higher recurrence rates, and side effects from radiation and immunotherapy can be serious.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.